10x Genomics Reports Third Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
10x Genomics (TXG) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
November 6, 2025 4:35 PM EST10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $149 million versus the consensus estimate of $142.5 million.
GUIDANCE:
10x Genomics sees Q4 2025 revenue of $154-158 million, versus the... More
